These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27038587)

  • 1. The therapeutic use of cannabinoids: Forensic aspects.
    Indorato F; Liberto A; Ledda C; Romano G; Barbera N
    Forensic Sci Int; 2016 Aug; 265():200-3. PubMed ID: 27038587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
    Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
    J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
    Contin M; Mancinelli L; Perrone A; Sabattini L; Mohamed S; Scandellari C; Foschi M; Vacchiano V; Lugaresi A; Riva R
    Clin Neuropharmacol; 2018; 41(5):171-176. PubMed ID: 30024443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.
    Lorente Fernández L; Monte Boquet E; Pérez-Miralles F; Gil Gómez I; Escutia Roig M; Boscá Blasco I; Poveda Andrés JL; Casanova-Estruch B
    Neurologia; 2014 Jun; 29(5):257-60. PubMed ID: 24035293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
    Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
    J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.
    Maniscalco GT; Aponte R; Bruzzese D; Guarcello G; Manzo V; Napolitano M; Moreggia O; Chiariello F; Florio C
    Neurol Sci; 2018 Jan; 39(1):97-102. PubMed ID: 29052091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.
    Fernández-Trapero M; Pérez-Díaz C; Espejo-Porras F; de Lago E; Fernández-Ruiz J
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32054131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration.
    Cherniakov I; Izgelov D; Barasch D; Davidson E; Domb AJ; Hoffman A
    J Control Release; 2017 Nov; 266():1-7. PubMed ID: 28890215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) method for the determination of cannabidiol (CBD), Δ
    Palazzoli F; Citti C; Licata M; Vilella A; Manca L; Zoli M; Vandelli MA; Forni F; Cannazza G
    J Pharm Biomed Anal; 2018 Feb; 150():25-32. PubMed ID: 29202305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
    Hložek T; Uttl L; Kadeřábek L; Balíková M; Lhotková E; Horsley RR; Nováková P; Šíchová K; Štefková K; Tylš F; Kuchař M; Páleníček T
    Eur Neuropsychopharmacol; 2017 Dec; 27(12):1223-1237. PubMed ID: 29129557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of antioxidants on the long-term stability of THC and related cannabinoids in sampled whole blood.
    Sørensen LK; Hasselstrøm JB
    Drug Test Anal; 2018 Feb; 10(2):301-309. PubMed ID: 28570781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabidiol modulation of antinociceptive tolerance to Δ
    Greene NZ; Wiley JL; Yu Z; Clowers BH; Craft RM
    Psychopharmacology (Berl); 2018 Nov; 235(11):3289-3302. PubMed ID: 30238130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of forensic specimens for cannabinoids. II. Relationship between blood delta 9-tetrahydrocannabinol and blood and urine 11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid concentrations.
    Moody DE; Monti KM; Crouch DJ
    J Anal Toxicol; 1992; 16(5):302-6. PubMed ID: 1338218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
    Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW
    Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sativex for the management of multiple sclerosis symptoms.
    Perras C
    Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part I: development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents.
    Manwell LA; Charchoglyan A; Brewer D; Matthews BA; Heipel H; Mallet PE
    J Pharmacol Toxicol Methods; 2014; 70(1):120-7. PubMed ID: 24973534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.
    Tanasescu R; Constantinescu CS
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1219-28. PubMed ID: 23621668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.
    Al-Ghezi ZZ; Busbee PB; Alghetaa H; Nagarkatti PS; Nagarkatti M
    Brain Behav Immun; 2019 Nov; 82():25-35. PubMed ID: 31356922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.